Opportunity stated the following:
"There is no other test that has this attribute. Other cancer tests are specific to a particular cancer type. Recaf detects CANCER, period. Any and all."
Not true. There happens to be several other universal markers. The HAAH marker is available and not selling. It has been on sale for two years and has had little commercial impact at all.
"This is not blind luck. It is a major discovery and Biocurex OWNS this technology. We can't own a molecule, but we can own the way that cancer is detected (and eventually cured)."
It appears to be quite apparent that Moro is unable to obtain a US patent for therapy or imaging. No pharmaceutical company is going to license RECAF therapy without a patent.
"The share price has been severely wounded because of manipulation (due to low volume) and let's be frank..... no revenues. We fix the revenue situation, then we simultaneously fix the volume which will disallow the manipulation. This will turn out to be an exceptional investment. JMHO. Good luck to all."
The share price is at this level because the largest diagnostic company in the world decided to NOT take RECAF into trials and to cease paying royalties. BioCurex also has a debt they have not been able to pay for 8 months. Moro has stated that the ELISA test was a quick shortcut to revenue. That was 13 months ago and no revenue nor licensees yet. Now, Dog RECAF is the new shortcut to revenue. One month and counting. Wittenberg, the Chairman, resigned last February and has apparently sold sold shares. Indeed good luck to all in this investment.
News 
Market Data 
Discover 
